Medical News Interviews
For atrial fibrillation, oral anti-coagulation remains the treatment of choice despite the potential of an anti-platelet regimen based on aspirin and clopidogrel, according to the ACTIVE-W trial. Stuart Connolly from McMaster University presented the findings.
[audio:https://www.audiomedica.com/podcasting/aha2005/Stuart_Connolly.mp3]
Click here for all the interviews from AHA 2005
RITA-3 Study Five Year Results: Aggressive Management of Acute Coronary Syndrome Now looks Even Better 12 Sep, 2005 Human Growth Hormone: Responses in Severe Heart Failure 17 Nov, 2005 Audio Journal of Cardiovascular Medicine: September 5th 2006 5 Sep, 2006 Immediate Angioplasty After Throbolysis Can Save Lives 3 Sep, 2007 
COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
